2,126 reports of this reaction
2.5% of all FULVESTRANT reports
#8 most reported adverse reaction
WHITE BLOOD CELL COUNT DECREASED is the #8 most commonly reported adverse reaction for FULVESTRANT, manufactured by AstraZeneca Pharmaceuticals LP. There are 2,126 FDA adverse event reports linking FULVESTRANT to WHITE BLOOD CELL COUNT DECREASED. This represents approximately 2.5% of all 86,552 adverse event reports for this drug.
Patients taking FULVESTRANT who experience white blood cell count decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHITE BLOOD CELL COUNT DECREASED is a less commonly reported adverse event for FULVESTRANT, but still significant enough to appear in the safety profile.
In addition to white blood cell count decreased, the following adverse reactions have been reported for FULVESTRANT:
The following drugs have also been linked to white blood cell count decreased in FDA adverse event reports:
WHITE BLOOD CELL COUNT DECREASED has been reported as an adverse event in 2,126 FDA reports for FULVESTRANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHITE BLOOD CELL COUNT DECREASED accounts for approximately 2.5% of all adverse event reports for FULVESTRANT, making it a notable side effect.
If you experience white blood cell count decreased while taking FULVESTRANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.